Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT00093678 Withdrawn - Pain Clinical Trials

Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer

Start date: n/a
Phase: N/A
Study type: Interventional

RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients. PURPOSE: This randomized clinical trial is studying celecoxib to see how well it works in managing pain, weight loss, and weakness in patients with advanced cancer.

NCT ID: NCT00085527 Withdrawn - Ovarian Cancer Clinical Trials

FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer

Start date: May 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with relapsed or refractory advanced ovarian epithelial cancer.

NCT ID: NCT00084370 Withdrawn - Ovarian Cancer Clinical Trials

Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy

Start date: June 2002
Phase: N/A
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib before prophylactic oophorectomy may be an effective way to prevent the development of ovarian epithelial cancer. PURPOSE: A controlled pilot trial to study the effectiveness of celecoxib in preventing cancer in patients at high-risk for ovarian epithelial cancer who are undergoing prophylactic oophorectomy.

NCT ID: NCT00080639 Withdrawn - Ovarian Cancer Clinical Trials

CA-125 in Screening Patients at High Risk for Ovarian Cancer

Start date: June 2003
Phase: Phase 2
Study type: Observational

RATIONALE: Measuring levels of CA 125 in blood samples of women who have a high risk of developing ovarian cancer may help doctors detect cancer early and plan more effective treatment. PURPOSE: This phase II trial is studying CA-125 levels in screening for cancer in women who are at high risk of developing ovarian cancer.

NCT ID: NCT00017537 Withdrawn - Breast Cancer Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer

Start date: March 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic or recurrent cancer.

NCT ID: NCT00006267 Withdrawn - Ovarian Cancer Clinical Trials

Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

Start date: n/a
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have recurrent or metastatic ovarian epithelial or primary peritoneal cancer.

NCT ID: NCT00005645 Withdrawn - Ovarian Cancer Clinical Trials

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

Start date: May 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or stage IV ovarian cancer that has not responded to previous therapy.

NCT ID: NCT00003865 Withdrawn - Ovarian Cancer Clinical Trials

Toremifene in Treating Patients With Ovarian Cancer

Start date: July 22, 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using toremifene may fight ovarian cancer by reducing the production of estrogen. PURPOSE: Randomized phase II trial to study the effectiveness of toremifene in treating patients who have recurrent or refractory ovarian cancer.